PARP1 and breast carcinoma: Olaparib was the first clinically approved PARP inhibitor, specifically for the treatment of ovarian carcinoma, peritoneal carcinoma, metastatic pancreatic cancer, metastatic castration-resistant prostate cancer as well as HER-2 negative breast cancer [12].